Genable deal taps into Spark’s gene therapy expertise
By Cormac Sheridan
Tuesday, March 25, 2014
DUBLIN – Genable Technologies Ltd. is dipping into Philadelphia’s deep pool of gene therapy expertise by entering a collaboration agreement with Spark Therapeutics LLC, under which the latter firm will provide manufacturing services and clinical development assistance on its lead program, GT038, currently in preclinical development for rhodopsin-linked autosomal dominant retinitis pigmentosa (RP).
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.